Hims & Hers Health a enregistré un chiffre d'affaires inférieur aux attentes au premier trimestre dans un contexte de pressions sur les marges.
L'entreprise s'éloigne des médicaments GLP-1 composés au profit de partenariats de marque avec Novo Nordisk et Eli Lilly. Ce changement devrait peser sur les marges à court terme tout en réduisant les risques juridiques associés à la préparation magistrale.
Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
Rapporté par l'IA
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
L’Oréal Group posted a 7.6% like-for-like revenue increase to €12.2 billion in the first quarter of fiscal 2026, exceeding analyst expectations. The results marked an acceleration from the previous quarter. CEO Nicolas Hieronimus credited innovation and e-commerce strength for global market share gains.
Rapporté par l'IA
Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.